Volume 1.32 | Aug 27

Prostate Cell News 1.32, August 27, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Resveratrol Regulates the PTEN/AKT Pathway through Androgen Receptor-Dependent and -Independent Mechanisms in Prostate Cancer Cell Lines 
This study demonstrates the mechanism by which androgen receptor regulates PTEN expression at the transcription level, indicating the direct link between a nuclear receptor and the PI3K/AKT pathway. [Hum Mol Genet]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



SCIENCE NEWS

Cost of Prostate Cancer Care Varies with Initial Treatment Choice
A new analysis has found that short-term and long-term costs of prostate cancer care vary considerably based on which treatment strategy a man initially receives. [Press release from EurekAlert! discussing online prepublication in Cancer]

Atrazine Causes Prostate Inflammation in Male Rats and Delays Puberty
A new study shows that male rats prenatally exposed to low doses of atrazine, a widely used herbicide, are more likely to develop prostate inflammation and to go through puberty later than non-exposed animals. [National Institutes of Health Press Release]

A Cluster Bomb for Cancer Care
Researchers have developed a nano-sized vehicle with the ability to deliver chemotherapy drugs directly into cancer cells while avoiding interaction with healthy cells, increasing the efficiency of chemotherapeutic treatment while reducing its side effects. [Tel Aviv University Press Release]

RoboSep_645x110_v02



LABORATORY RESEARCH

A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules
The results provide critical insights into the design of prostate specific membrane antigen-targeted small molecules for prostate cancer diagnosis and treatment; more broadly, the presence of similar arene-binding sites throughout the proteome could prove widely enabling in the optimization of small molecule-protein interactions. [J Am Chem Soc]

Matrix Metalloproteinase-9 Regulates Tumor Cell Invasion through Cleavage of Protease Nexin-1
This study shows a novel molecular pathway in which matrix metalloproteinase-9 regulates uPA activity and tumor cell invasion through cleavage of serpin protease nexin-1. [Cancer Res]

Biocompatible Magnetofluorescent Probes: Luminescent Silicon Quantum Dots Coupled with Superparamagnetic Iron(III) Oxide
Here, researchers report the development of a multimodal probe that combines the optical properties of silicon quantum dots with the superparamagnetic properties of iron oxide nanoparticles to create biocompatible magnetofluorescent nanoprobes. [ACS Nano]

ZEB1 Coordinately Regulates Laminin-332 and Beta4 Integrin Expression Altering the Invasive Phenotype of Prostate Cancer Cells
Here, researchers report that TEM4-18 cells express significantly reduced levels of two subunits of laminin-332 (Beta3 and Gamma2) and that exogenous laminin-332, or co-culture with laminin-332-expressing cells, rescues the in vitro invasion phenotype in these cells. [J Biol Chem]

DHT Selectively Reverses Smad3-Mediated/ TGF-Beta-Induced Responses through Transcriptional Down-Regulation of Smad3 in Prostate Epithelial Cells
The findings suggest that deregulated/enhanced expression and activation of androgen receptor in prostate carcinomas may intercept the tumor suppressor function of TGF-beta through transcriptional suppression of Smad3, thereby providing new mechanistic insight into the development of castration-resistant prostate cancer. [Mol Endocrinol]

Activating Stress-Activated Protein Kinase-Mediated Cell Death and Inhibiting Epidermal Growth Factor Receptor Signaling: A Promising Therapeutic Strategy for Prostate Cancer
The goal of this study was to determine whether the natural compound psoralidin alters epidermal growth factor receptor-mediated signaling resulting in the inhibition of prostate cancer growth. [Mol Cancer Ther]

Effects of Prenatal Exposure to a Low Dose Atrazine Metabolite Mixture on Pubertal Timing and Prostate Development of Male Long-Evans Rats
The present study examines the postnatal reproductive development of male rats following prenatal exposure to an atrazine metabolite mixture (AMM) consisting of the herbicide atrazine and its environmental metabolites diaminochlorotriazine, hydroxyatrazine, deethylatrazine, and deisopropylatrazine. [Reprod Toxicol]

CLINICAL RESEARCH

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Treatment with OGX-011 and docetaxel was well tolerated with evidence of biologic effect and was associated with improved survival. [J Clin Oncol]

The Relationship Between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group
Researchers hypothesized that the risk of prostate cancer on biopsy for a given PSA level is affected by identifiable characteristics of the cohort under study. [Clin Cancer Res]

How Does Initial Treatment Choice Affect Short-Term and Long-Term Costs for Clinically Localized Prostate Cancer?
This study investigates how initial treatment choice affects short-term and long-term costs. [Cancer]



INDUSTRY NEWS

BIND Biosciences Presents Preclinical Data for Novel Nanomedicine, BIND-014, at American Chemical Society National Meeting
BIND Biosciences announced the presentation of its Medicinal Nanoengineering™ platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year. [BIND Biosciences, Inc. Press Release]

Stem Cell Agency Commits $243 Million, Expands Team Approach to Developing New Therapies
The Governing Board of the California Institute for Regenerative Medicine, the state stem cell agency created by proposition 71, approved the concept for up to $243 million round of funding to move stem cell-based therapies to clinical trial. [California Institute for Regenerative Medicine Press Release]

Sanofi Seeks Efficiencies with New Model
Sanofi-aventis is dividing its vast resources into decentralized disease-based units, each with its own departments for research and development, regulatory affairs, marketing, and sales — a plan designed to identify promising drugs more quickly and weed out failures before spending billions on unsuccessful clinical trials. [The Boston Globe]



POLICY NEWS

Lawrence A. Tabak Named Principal Deputy Director NIH
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announced the appointment of Lawrence A. Tabak, D.D.S., Ph.D., as principal deputy director of the National Institutes of Health. [National Institutes of Health, United States]

Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) (RFA-GM-11-003) [National Institutes of Health, United States]

Proposed Collection; Comment Request; STAR METRICS–Science and Technology in America’s Reinvestment: Measuring the Effects of Research on Innovation, Competitiveness and Science (FR Doc. 2010-20614) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-20287) [National Institutes of Health, United States]

Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-20675) [National Institutes of Health, United States]

NIH-RAID Updates on Program Scope and Procedures: Biologics Manufacture, Lead Selection, and Product Development Plans (NOT-RM-10-012) [National Institutes of Health, United States]

Support of National Institute of General Medical Sciences Program Project Grants (P01) (PAR-10-266) [National Institutes of Health, United States]

Complete List of Currently Approved NDA and ANDA Application Submissions (PDF – 62KB)   [Food and Drug Administration, United States]



EVENTS (Listed by Date)

The Science of Global Prostate Cancer Disparities in Black Men
August 27-29, 2010
Jacksonville, United States

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

Prostate Cancer Research Institute Conference 2010
September 11-12, 2010
Los Angeles, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

2010 Prostate Cancer Canada (PCCN) Conference
September 22-25, 2010
Toronto, Canada


International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Cancer Pharmacogenetics: Personalising Medicine
November 22-24, 2010
Madrid, Spain

IMPaCT: Innovative Minds in Prostate Cancer Today 2011
March 9-12, 2011
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News.
Visit here to post your career opportunities.


Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us